Search results for "CD3"

showing 10 items of 420 documents

Granulocyte–Colony Stimulating Factor plus Plerixafor in Patients with β-thalassemia Major Results in the Effective Mobilization of Primitive CD34+ C…

2017

Successful gene therapy for β-thalassemia requires optimal numbers of autologous gene-transduced hematopoietic stem and progenitor cells (HSPCs) with high repopulating capacity. Previous studies suggested superior mobilization in these patients by the combination of granulocyte–colony stimulating factor (G-CSF) plus plerixafor over single agents. We mobilized four adult patients using G-CSF+plerixafor to assess the intra-individual variation of the circulating CD34+ cells number and subtypes preand post-plerixafor administration. The procedure was well-tolerated and the target cell dose of ≥8×10 6 CD34+ cells/kg was achieved in three of them with one apheresis procedure. The addition of ple…

Mobilizationbusiness.industryCD34+ cells expression profilingCd34 cellsPlerixaforGenetic enhancementβ-thalassemia; CD34 cells expression profiling; G-CSF plerixafor mobilization; gene therapygene therapySettore MED/15 - Malattie Del SangueGranulocyte colony-stimulating factorSettore BIO/18 - Geneticagene therapy.β-thalassemiaGene expressionImmunologyCancer researchG-CSF+plerixafor mobilizationMedicineDiseases of the blood and blood-forming organsIn patientβ-thalassemia; CD34+ cells expression profiling; G-CSF+plerixafor mobilization; gene therapyRC633-647.5businessβ thalassemia majormedicine.drugThalassemia Reports
researchProduct

Growth kinetics and characterization of human dental pulp stem cells: Comparison between third molar and first premolar teeth

2015

Background Dental pulp stem cells (DPSCs) play an important role in tissue regeneration. This study compares the growth kinetics and characterization of third molar and first premolar human DPSCs. Material and Methods Dental pulp tissues were isolated from human first premolar and third molar teeth and were digested by treating them with collagenase type I. Single-cell suspensions from each dental pulp were seeded in T25 culture flasks and the media were replaced every 3 days until 70% confluence. The cells were enumerated to determine the population doubling time (PDT). Cells were characterized using flow cytometry, RT-PCR and osteogenic medium for differentiation of DPSCs. Karyotyping ass…

MolarCD34DentistryOdontologíaOperative Dentistry and EndodonticsAndrology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinestomatognathic systemTissue engineeringDental pulp stem cellsPremolarmedicineCD90General Dentistrybusiness.industryChemistryResearchMesenchymal stem cell030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludstomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASStem cellbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Tumor Control in a Model of Bone Marrow Transplantation and Acute Liver-Infiltrating B-Cell Lymphoma: an Unpredicted Novel Function of Cytomegalovirus

2002

ABSTRACTTumor relapse and cytomegalovirus (CMV) infection are major concerns in the therapy of hematopoietic malignancies by bone marrow transplantation (BMT). Little attention so far has been given to a possible pathogenetic interplay between CMV and lymphomas. CMV inhibits stem cell engraftment and hematopoietic reconstitution. Thus, by causing maintenance of bone marrow aplasia and immunodeficiency, CMV could promote tumor relapse. Alternatively, CMV could aid tumor remission. One might think of cytopathogenic infection of tumor cells, induction of apoptosis or inhibitory cytokines, interference with tumor cell extravasation or tumor vascularization, or bystander stimulation of an antitu…

MuromegalovirusLymphoma B-CellCD30ImmunologyBone Marrow AplasiaBiologyMicrobiologyMiceImmune systemhemic and lymphatic diseasesVirologyTumor Cells CulturedmedicineAnimalsCytotoxic T cellB-cell lymphomaBone Marrow TransplantationMice Inbred BALB CTumor Necrosis Factor-alphamedicine.diseaseLymphomaDisease Models AnimalHaematopoiesisLiverInsect ScienceCytomegalovirus InfectionsImmunologyPathogenesis and ImmunityStem cellJournal of Virology
researchProduct

Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors

1998

Cell cycle control of both immature and differentiated primary myeloid normal and chronic-phase chronic myeloid leukaemia (CML) cells to growth factor deprivation was studied. CD34+ cells were cultured in liquid culture. After removal of growth factors for 48 h normal cells were very efficiently arrested with the fraction of cells in S phase reduced by 70.8 +/- 6.5% in CD34+ and 50.5 +/- 4.2% in CD34- cells. In contrast, a significantly higher proportion of leukaemic cells remained in S phase. The fraction of S-phase cells was reduced by only 29.3 +/- 5.7% in CD34+ CML cells and 21.2 +/- 3.8% in CD34- cells. This abnormal negative cell cycle control in leukaemic cells was specific for growt…

MyeloidCell growthGrowth factormedicine.medical_treatmentCD34HematologyBiologyCell cyclemedicine.diseaseLeukemiamedicine.anatomical_structureImatinib mesylateCytokinehemic and lymphatic diseasesmedicineCancer researchBritish Journal of Haematology
researchProduct

Signalling through TLR2/MyD88 induces differentiation of murine bone marrow stem and progenitor cells to functional phagocytes in response to Candida…

2009

Summary We have previously demonstrated that inactivated yeasts and hyphae of Candida albicans induce in vitro the proliferation of murine haematopoietic stem and progenitor cells (HSPCs, sorted as LKS cells: Lin - c-Kit + Sca-1 + ) as well as their differentia- tion to lineage-positive cells, through a MyD88- dependent pathway. In this work, we have found that this process is mainly mediated by TLR2, and that expanding cells express myeloid and not lym- phoid markers. Incubation of long-term repopulat- ing HSCs (Lin - CD105 + and Sca-1 + ) with C. albicans yeasts resulted in their proliferation and up regu- lation of the common myeloid progenitors (CMPs) markers, CD34 and FcgRII/III, by a …

MyeloidCellular differentiationImmunologyCD34Bone Marrow CellsMicrobiologyMiceVirologyCandida albicansmedicineMacrophageAnimalsAntigens LyProgenitor cellCandida albicansCells CulturedPhagocytesCD11b AntigenbiologyStem CellsCell Differentiationbiology.organism_classificationFlow CytometryAntigens DifferentiationMice Mutant StrainsToll-Like Receptor 2Cell biologyHaematopoiesismedicine.anatomical_structureMyeloid Differentiation Factor 88Bone marrowSignal TransductionCellular microbiology
researchProduct

CXCR3-ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.

2007

Background Lichenoid graft-versus-host disease (liGVHD) histologically shares several common features with other lichenoid dermatoses, such as cutaneous lupus erythematosus and lichen planus (LP), which collectively show a junctional infiltrate of cytotoxic lymphocytes with liquefaction of the basal layer ("interface dermatitis"). Because recent studies have shown a role for type I interferon (IFN)–associated inflammation, including lymphocyte recruitment via CXCR3 ligand interaction in cutaneous lupus erythematosus and LP, we hypothesized that similar mechanisms might also be involved in liGVHD. Methods Ten representative lesional skin biopsies taken from patients with different subsets of…

Myxovirus Resistance ProteinsChemokinePathologymedicine.medical_specialtyLichenoid EruptionsReceptors CXCR3CD3T-LymphocytesGraft vs Host DiseaseInflammationDermatitisDermatologyIn situ hybridizationCXCR3LigandsChemokine CXCL9Skin DiseasesGTP-Binding ProteinsMedicineCXCL10HumansLymphocytesRNA MessengerIn Situ Hybridizationbiologybusiness.industryLichen PlanusInterferon-alphaChemokine CXCL10stomatognathic diseasesImmunologyChronic DiseaseInterferon Type Ibiology.proteinCXCL9Immunohistochemistrymedicine.symptomEpidermisbusinessJournal of the American Academy of Dermatology
researchProduct

Unvolvement of calcium signaling and MAP kinases in lipid taste perception

2013

In this work, we demonstrate that stromal interaction molecule 1 (STIM1), a sensor of Ca2+ depletion in the endoplasmic reticulum, mediates fatty acid–induced Ca2+ signaling in the mouse tongue and fat preference. We showed that linoleic acid (LA) induced the production of arachidonic acid (AA) and lysophosphatidylcholine (Lyso-PC) by activating multiple phospholipase A2 isoforms via CD36. This activation triggered Ca2+ influx in lingual CD36-positive taste bud cells (TBCs) purified from mouse CVP. LA also induced the production of Ca2+ influx factor (CIF). STIM1 was found to regulate LA-induced CIF production and the opening of store-operated Ca2+ (SOC) channels. Furthermore, CD36-positive…

NTS[SDV.MHEP.AHA] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]SerotoninZif268[ SDV.MHEP.AHA ] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Arcuate nucleuSérotonineMAP KinasesPapille caliciformeHippocampusCircumvallate papillaeOrai1/3Noyau arqué[ SDV.BBM.BC ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM][SDV.MHEP.AHA]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO][SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM][SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM]PLA2HippocampePréférence gustative lipidiqueLipid taste perceptionGlut1MAPKALBDNFStim1CD36
researchProduct

Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients.

2010

Up to 10% of germ cell tumor patients require salvage high-dose chemotherapy with stem cell support, achieving cure rates in the range of 10-60%. Stem cell mobilization may be difficult in these patients because of multiple lines of treatment known to seriously hamper stem cell recovery. Plerixafor significantly enhances the success of the CD34+ cell harvest, even in cases where prior mobilization attempts have failed. Six germ cell tumor patients provided informed consent and were included in the compassionate use program. All patients were heavily pretreated, with a median of 3.5 prior lines of therapy. All failed prior mobilization with G-CSF in combination with chemotherapy. Five patien…

OncologyAdultCompassionate Use TrialsMalemedicine.medical_specialtyBenzylaminesPlatelet Engraftmentmedicine.medical_treatmentCD34Hematopoietic stem cell transplantationCyclamsYoung AdultTesticular NeoplasmsHeterocyclic CompoundsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansUltrasonographyTransplantationChemotherapyMobilizationbusiness.industryPlerixaforHematopoietic Stem Cell TransplantationHematologyMiddle AgedNeoplasms Germ Cell and EmbryonalCombined Modality TherapyHematopoietic Stem Cell MobilizationSurgerySeminomamedicine.anatomical_structureStem cellbusinessGerm cellmedicine.drugBone marrow transplantation
researchProduct

Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy i…

2002

The purpose of this study was to evaluate feasibility and efficacy of Rituximab included into a sequential salvage protocol for CD20(+) B-NHL in relapse or induction failure. Twenty-seven patients with CD20(+) B-NHL in relapse or induction failure received Rituximab combined with DexaBEAM (R-DexaBEAM) for stem cell mobilization. Additional ex vivo selection of CD34-positive cells was performed using the CliniMacs device. Two doses of Rituximab were included in the high-dose therapy regimen (HDT). R-DexaBEAM was well tolerated and 26 of 27 patients mobilized sufficient numbers of CD34(+) blood stem cells. Application of R-DexaBEAM resulted in significant depletion of peripheral B cells. No t…

OncologyAdultMalemedicine.medical_specialtyLymphoma B-CellSalvage therapyAggressive lymphomaAntigens CD34Transplantation AutologousDisease-Free SurvivalAntibodies Monoclonal Murine-DerivedAutologous stem-cell transplantationhemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesCD20Salvage TherapyTransplantationPeripheral Blood Stem Cell Transplantationbiologybusiness.industryBone Marrow PurgingRemission InductionAntibodies MonoclonalHematologyMiddle AgedNeoplastic Cells CirculatingHematopoietic Stem Cell MobilizationSurgeryHematopoiesisTransplantationRegimenImmune Systembiology.proteinRituximabFemaleVirus ActivationStem cellbusinessRituximabmedicine.drugBone marrow transplantation
researchProduct

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers

2019

BACKGROUND: Approximately 4% of colorectal cancer (CRC) patients have at least two simultaneous cancers in the colon. Due to the shared environment, these synchronous CRCs (SCRCs) provide a unique setting to study colorectal carcinogenesis. Understanding whether these tumours are genetically similar or distinct is essential when designing therapeutic approaches. METHODS: We performed exome sequencing of 47 primary cancers and corresponding normal samples from 23 patients. Additionally, we carried out a comprehensive mutational signature analysis to assess whether tumours had undergone similar mutational processes and the first immune cell score analysis (IS) of SCRC to analyse the interplay…

OncologyMaleCancer ResearchPROGNOSISCD3 ComplexColorectal cancerFEATURESmedicine.medical_treatmentDNA Mutational AnalysisCD8-Positive T-Lymphocytesmedicine.disease_causeTargeted therapyNeoplasms Multiple Primary0302 clinical medicineMUTATIONAL PROCESSESExomeLymphocytesExomeCancer geneticsExome sequencingAged 80 and overMutationMETHYLATIONMiddle Aged3. Good healthOncology030220 oncology & carcinogenesisDNA mismatch repairFemaleMicrosatellite InstabilityKRASColorectal Neoplasmsmedicine.medical_specialtyCARCINOMACD8 Antigens3122 Cancerscancer geneticscolorectal cancersuolistosyövätBiologyArticle03 medical and health sciencesCOLONInternal medicineKRASmedicineHumansSIGNATURESIMMUNOSCOREAgedDNA-analyysiMicrosatellite instabilitymedicine.diseaseColorectal cancerCase-Control StudiesMutationBritish Journal of Cancer
researchProduct